LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Villesuzanne, Camille"
  2. AU="Daoudi, A"
  3. AU=Trombini Amanda B
  4. AU="Ravender, Raja"
  5. AU="Sheng, Honghao"
  6. AU="Bezler, Valerie"
  7. AU="Kevin Rostásy"
  8. AU=van Helden Mary J.
  9. AU="Grzegorz Adamczyk"
  10. AU="Longo, M"
  11. AU="Debarnot, Cecilé"
  12. AU="Thomas, Sophie"
  13. AU=Steyer Terence E AU=Steyer Terence E
  14. AU="Retrouvey, Jean-Marc"
  15. AU="Crecchio, Carmine"
  16. AU=Moll Philip J. W.
  17. AU="Coombs, Catherine C"
  18. AU="Safaei, Naser"
  19. AU="Bachouche, Imene"
  20. AU="Roignant, Jean-Yves"
  21. AU="Thabet, Nagwa"
  22. AU="Asor, Eyal"
  23. AU="Rahaman, Md Hasibur"
  24. AU="Angela Di Capua"
  25. AU=De Vitis R
  26. AU="Young, Kaelin C"

Suchergebnis

Treffer 1 - 7 von insgesamt 7

Suchoptionen

  1. Artikel ; Online: Amylose AL, du diagnostic au traitement.

    Villesuzanne, Camille / Jaccard, Arnaud / Nicol, Martin

    La Revue du praticien

    2021  Band 70, Heft 10, Seite(n) 1137–1141

    Abstract: Al amyloidosis, from diagnosis to treatment. AL amyloidosis is a rare hemopathy characterized by immunoglobulin light chains deposits in almost all organs causing organ failure. The main issue is the early diagnosis, which must be made in front of an ... ...

    Titelübersetzung AL amyloidosis, from diagnosis to treatment.
    Abstract Al amyloidosis, from diagnosis to treatment. AL amyloidosis is a rare hemopathy characterized by immunoglobulin light chains deposits in almost all organs causing organ failure. The main issue is the early diagnosis, which must be made in front of an unexplained non-specific symptomatology, especially cardiac or renal, in frequently elderly patients with monoclonal gammopathy. Non-invasive biopsies should be made for histological confirmation revealing positive congo red and birefringent yellow-green deposits in polarized light specific for amyloidosis. Severity is assessed by biological markers of cardiac involvement. The treatment consists in eliminating the plasma or lympho-plasma cell dyscrasia secreting the amyloidogenic light chain, and in proposing supportive care specific to this pathology.
    Mesh-Begriff(e) Aged ; Amyloidosis/diagnosis ; Amyloidosis/therapy ; Humans ; Immunoglobulin Light Chains ; Immunoglobulin Light-chain Amyloidosis/diagnosis ; Immunoglobulin Light-chain Amyloidosis/therapy ; Kidney ; Paraproteinemias/diagnosis ; Paraproteinemias/therapy
    Chemische Substanzen Immunoglobulin Light Chains
    Sprache Französisch
    Erscheinungsdatum 2021-03-19
    Erscheinungsland France
    Dokumenttyp Journal Article
    ZDB-ID 205365-2
    ISSN 2101-017X ; 0035-2640
    ISSN (online) 2101-017X
    ISSN 0035-2640
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Heavy chain/light chain assay is a useful biomarker for diagnosis and management of patients with cold agglutinin disease.

    Ursule-Dufait, Cindy / Bengoufa, Djaouida / Theodorou, Ioannis / Villesuzanne, Camille / Arnulf, Bertrand

    British journal of haematology

    2022  Band 198, Heft 4, Seite(n) e67–e70

    Mesh-Begriff(e) Anemia, Hemolytic, Autoimmune/diagnosis ; Anemia, Hemolytic, Autoimmune/therapy ; Biomarkers ; Humans ; Immunoglobulin Light Chains ; Paraproteinemias/diagnosis
    Chemische Substanzen Biomarkers ; Immunoglobulin Light Chains
    Sprache Englisch
    Erscheinungsdatum 2022-06-22
    Erscheinungsland England
    Dokumenttyp Letter
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.18317
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment.

    Abecassis, Audrey / Roders, Nathalie / Fayon, Maxime / Choisy, Caroline / Nelson, Elisabeth / Harel, Stephanie / Royer, Bruno / Villesuzanne, Camille / Talbot, Alexis / Garrick, David / Goodhardt, Michele / Fermand, Jean-Paul / Burbridge, Mike / Arnulf, Bertrand / Bories, Jean-Christophe

    EJHaem

    2022  Band 3, Heft 3, Seite(n) 970–974

    Abstract: Chimeric antigen receptor T cells (CAR-T) have provided promising results in multiple myeloma (MM). However, many patients still relapse, pointing toward the need of improving this therapy. Here, we analyzed peripheral blood T cells from MM patients at ... ...

    Abstract Chimeric antigen receptor T cells (CAR-T) have provided promising results in multiple myeloma (MM). However, many patients still relapse, pointing toward the need of improving this therapy. Here, we analyzed peripheral blood T cells from MM patients at different stages of the disease and investigated their phenotype and capacity to generate functional CAR-T directed against CS1 or B Cell Maturation antigen. We found a decrease in naive T cells and elevated frequencies of exhaustion markers in T cells from treated MM patients. Interestingly, individuals treated with daratumumab display elevated ratios of central memory T cells. CAR-T derived from patients at relapse show reduced in vitro expansion and cytotoxic capacities in response to MM cells compared to those produced at diagnosis. Of note, CAR-T from daratumumab treated patients display intermediate defects. Reduced anti-myeloma activity of CAR T cells from treated patients was also observed in a mouse model. Our findings suggest that T cell defects in MM patients, specifically during relapse, have a major impact on their capacity to generate efficient therapeutic CAR-T. Selecting naive or central memory T cell subsets to generate therapeutic T cells could improve the CAR-T therapy for MM.
    Sprache Englisch
    Erscheinungsdatum 2022-06-21
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ISSN 2688-6146
    ISSN (online) 2688-6146
    DOI 10.1002/jha2.479
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Inflammatory Waldenström's macroglobulinaemia: A French monocentric retrospective study of 67 patients.

    Elessa, Dikelele / Debureaux, Pierre-Edouard / Villesuzanne, Camille / Davi, Frederic / Bravetti, Clotilde / Harel, Stephanie / Talbot, Alexis / Oksenhendler, Eric / Malphettes, Marion / Thieblemont, Catherine / Moatti, Hannah / Maarek, Odile / Arnulf, Bertrand / Royer, Bruno

    British journal of haematology

    2022  Band 197, Heft 6, Seite(n) 728–735

    Abstract: Waldenström's macroglobulinaemia (WM) is a B-cell neoplasm resulting from bone marrow lymphoplasmacytic infiltration and monoclonal IgM secretion. Some patients present concomitant inflammatory syndrome attributed to the disease activity; we named this ... ...

    Abstract Waldenström's macroglobulinaemia (WM) is a B-cell neoplasm resulting from bone marrow lymphoplasmacytic infiltration and monoclonal IgM secretion. Some patients present concomitant inflammatory syndrome attributed to the disease activity; we named this syndrome inflammatory WM (IWM). We retrospectively analysed all WM patients seen in a single tertiary referral centre from January 2007 to May 2021, and after excluding aetiologies for the inflammatory syndrome using a pertinent blood workup, including C-reactive protein (CRP), and imaging, we identified 67 (28%) IWM, 166 (68%) non-IWM, and nine (4%) WM with inflammatory syndrome of unknown origin. At treatment initiation, IWM patients had more severe anaemia (median Hb 90 vs 99 g/l; p < 0.01), higher platelet count (median 245 vs 196 × 109/l; p < 0.01) and comparable serum IgM level (median 24.9 vs 23.0 g/l; p = 0.28). A positive correlation was found between inflammatory and haematological responses (minimal response or better) (odds ratio 32.08; 95% confidence interval 8.80-98.03; p < 0.001). Overall survivals (OS) were similar (median OS: 17 vs 20 years; p = 0.11) but time to next treatment (TNT) was significantly shorter for IWM (TNT1: 1.6 vs 4.8 years, p < 0.0001). IWM mostly shared the same presentation and outcome as WM without inflammatory syndrome.
    Mesh-Begriff(e) Humans ; Immunoglobulin M ; Retrospective Studies ; Waldenstrom Macroglobulinemia
    Chemische Substanzen Immunoglobulin M
    Sprache Englisch
    Erscheinungsdatum 2022-04-08
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.18157
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases.

    Vergneault, Hélène / Bengoufa, Djaouida / Frazier-Mironer, Aline / Brocheriou, Isabelle / Bitoun, Samuel / Villesuzanne, Camille / Talbot, Alexis / Harel, Stéphanie / Arnulf, Bertrand / Royer, Bruno

    Haematologica

    2021  Band 106, Heft 7, Seite(n) 2034–2036

    Mesh-Begriff(e) Aged ; Female ; Heavy Chain Disease ; Humans ; Male ; Proteinuria/diagnosis ; Proteinuria/etiology ; Waldenstrom Macroglobulinemia/complications ; Waldenstrom Macroglobulinemia/diagnosis
    Sprache Englisch
    Erscheinungsdatum 2021-07-01
    Erscheinungsland Italy
    Dokumenttyp Case Reports ; Journal Article
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2020.277137
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: Thromboembolism and bleeding in systemic amyloidosis: a review.

    Nicol, Martin / Siguret, Virginie / Vergaro, Giuseppe / Aimo, Alberto / Emdin, Michele / Dillinger, Jean Guillaume / Baudet, Mathilde / Cohen-Solal, Alain / Villesuzanne, Camille / Harel, Stephanie / Royer, Bruno / Arnulf, Bertrand / Logeart, Damien

    ESC heart failure

    2021  Band 9, Heft 1, Seite(n) 11–20

    Abstract: The assessment of both thromboembolic and haemorrhagic risks and their management in systemic amyloidosis have been poorly emphasized so far. This narrative review summarizes main evidence from literature with clinical perspective. The rate of ... ...

    Abstract The assessment of both thromboembolic and haemorrhagic risks and their management in systemic amyloidosis have been poorly emphasized so far. This narrative review summarizes main evidence from literature with clinical perspective. The rate of thromboembolic events is as high as 5-10% amyloidosis patients, at least in patients with cardiac involvement, with deleterious impact on prognosis. The most known pro-thrombotic factors are heart failure, atrial fibrillation, and atrial myopathy. Atrial fibrillation could occur in 20% to 75% of systemic amyloidosis patients. Cardiac thrombi are frequently observed in patients, particularly in immunoglobulin light chains (AL) amyloidosis, up to 30%, and it is advised to look for them systematically before cardioversion. In AL amyloidosis, nephrotic syndrome and the use of immunomodulatory drugs also favour thrombosis. On the other hand, the bleeding risk increases because of frequent amyloid digestive involvement as well as factor X deficiency, renal failure, and increased risk of dysautonomia-related fall.
    Mesh-Begriff(e) Amyloid ; Amyloidosis/complications ; Amyloidosis/diagnosis ; Heart Failure ; Humans ; Immunoglobulin Light-chain Amyloidosis/complications ; Thromboembolism/etiology
    Chemische Substanzen Amyloid
    Sprache Englisch
    Erscheinungsdatum 2021-11-16
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2814355-3
    ISSN 2055-5822 ; 2055-5822
    ISSN (online) 2055-5822
    ISSN 2055-5822
    DOI 10.1002/ehf2.13701
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Characteristics and mid-term follow-up of COVID-19 patients with hematological diseases: a retrospective study from a French tertiary care hospital.

    Vallet, Nicolas / Chevret, Sylvie / Feghoul, Linda / Aguinaga, Lorea / Bondeelle, Louise / Kaphan, Eleonore / Bertinchamp, Rémi / Soret, Juliette / Villesuzanne, Camille / De Castro, Nathalie / Sebert, Marie / Boutboul, David / Lengline, Etienne / Tudesq, Jean-Jacques / Rabian, Florence / Adès, Lionel / Xhaard, Alienor / Di Blasi, Roberta / Raffoux, Emmanuel /
    Galicier, Lionel / Le Goff, Jérôme / Delaugerre, Constance / Bergeron, Anne / Harel, Stéphanie

    Blood cancer journal

    2021  Band 11, Heft 7, Seite(n) 129

    Mesh-Begriff(e) COVID-19/complications ; Follow-Up Studies ; France ; Hematologic Diseases/complications ; Humans ; Retrospective Studies ; SARS-CoV-2 ; Tertiary Care Centers
    Sprache Englisch
    Erscheinungsdatum 2021-07-14
    Erscheinungsland United States
    Dokumenttyp Letter
    ZDB-ID 2600560-8
    ISSN 2044-5385 ; 2044-5385
    ISSN (online) 2044-5385
    ISSN 2044-5385
    DOI 10.1038/s41408-021-00512-5
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang